EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

China Isotope Radiation Corporation (1763) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of China Isotope Radiation Corporation HK$22.63, price HK$13.14, upside +72.2%, quality 49 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · HK · Home China · ISIN CNE1000031F4

CI Some data Oct 1, 2026

China Isotope Radiation Corporation

1763 · HK

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

✓Fair value HK$22.63 · Strongly undervalued (+72.2%)
!Quality 49/100
!Expensive Growth (revenue 5y +10.4 %/yr)
!Thin margins · 4.5% net margin (TTM)
!Low debt · negative free cash flow
!2.5% dividend yield · Watch coverage
✓Ranks above peers (9/13)
!Narrow moat 41/100
!Evidence only medium, so the estimate is less certain
!Weak on future: 22 out of 100
Watch China Isotope Radiation Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$26.83 HK$8.24 Fair Value HK$22.63 May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.

How to read this chart

60‑month range HK$8.24 – HK$26.83 · fair‑value band HK$15.84 – HK$29.43 · the HK$13.14 price screens below the HK$22.63 fair value. Dashed = 300-day average. As of Oct 1, 2026.

Follow China Isotope Radiation in your weekly email

Every Wednesday you see whether China Isotope Radiation is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of nuclides, diagnostic, and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China.

Show more

China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of nuclides, diagnostic, and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. The company operates through five segments: Nuclear Medicines; Radioactive Source Products; Irradiation; Nuclear Medical Equipment and Related Services; and Other Businesses. The Nuclear Medicines segment engages in research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals, urea breath test diagnostic kits, test analyzers, and other products. The Radioactive Source Products segment sells medical and industrial radioactive sources products and related technical services. The Irradiation segment offers irradiation services to manufacturers of medical devices, pharmaceuticals, cosmetics, and food for sterilization, and provides design, manufacturing, and installation of gamma ray irradiation facilities and related technical services. The Nuclear Medical Equipment and Related Services segment sells nuclear medical equipment and provides related maintenance services. The Other Businesses segment provides trade services for nuclear technology industry applications, medical product applications, technical services, and sales of medical devices. This segment also offers independent clinical laboratory services for nuclear technology industry applications and medical product applications; and provides radioactive sources, medical nuclides, imported radiopharmaceuticals, nuclear instruments and devices, medical equipment and other products. The company was incorporated in 1983 and is headquartered in Beijing, China. China Isotope & Radiation Corporation operates as a subsidiary of China National Nuclear Corporation.

Stock analysis

China Isotope Radiation Corporation (1763) currently trades at HK$13.14, while our model-based Fair Value estimate is HK$22.63, implying the stock looks roughly 41.9% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of HK$25.63 per share, and 13 of the 17 models we run sit above the HK$13.14 price.

Bear case: the Dividend Discount group reads lowest at HK$5.82, and 4 of the 17 models stay below the price. Evidence for this calculation is medium.

Scenario range: HK$15.84 (bear) to HK$29.43 (bull), the price of HK$13.14 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

China Isotope Radiation Corporation reported revenue of 7.0B CNY in FY2025 versus 5.1B CNY in FY2021, a compound +8.0%/yr. Reported net income was 319M CNY in FY2025, compounding −1.3%/yr from FY2021.

Key figures

Market cap HK$4.2B (≈ $536M) · P/E ratio 11.0 · P/S ratio 0.50 · Dividend yield 2.5% · Net margin 4.6% · Return on equity 8.2% · Return on assets (EBIT) 7.1% · Operating margin 15.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 45% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 72%, 1763 screens cheaper than that median.

Fair Value models

Bear HK$15.84 Fair Value HK$22.63 Bull HK$29.43
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings HK$6.01 HK$7.95 HK$10.92 77
Residual Income HK$14.23 HK$14.40 HK$15.31 76
EPV HK$20.20 HK$22.53 HK$24.47 74
All 17 models by family
DCF Models
Owner Earnings HK$6.01 HK$7.95 HK$10.92 77
Earnings-Based
Graham-Dodd HK$7.92 HK$36.71 HK$50.42 64
Lynch FV HK$9.67 HK$13.82 HK$17.96 61
PEG = 1.0 HK$9.67 HK$13.82 HK$17.96 57
EPV HK$20.20 HK$22.53 HK$24.47 74
Dividend Discount
Gordon GGM HK$3.54 HK$6.38 HK$8.78 68
DDM Multi-Stage HK$3.54 HK$5.82 HK$6.81 67
Multiples
P/E Multiple HK$19.22 HK$25.63 HK$32.04 63
P/S Multiple HK$14.86 HK$19.81 HK$24.76 58
P/B Multiple HK$14.86 HK$19.81 HK$24.76 55
EV/EBIT HK$45.76 HK$59.99 HK$74.21 66
EV/EBITDA HK$48.38 HK$63.47 HK$78.57 67
EV/Revenue HK$33.55 HK$46.60 HK$59.65 54
Asset-Based
NCAV (Graham) HK$9.55 HK$12.80 HK$19.10 54
Economic Profit
Residual Income HK$14.23 HK$14.40 HK$15.31 76
ROIC Compounder HK$20.64 HK$25.25 HK$31.29 72
Growth Earnings
Growth-Adj P/E HK$15.84 HK$22.63 HK$29.43 67

Open the full fair value analysis →

Notify me when 1763 reaches fair value

Put 1763 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 49/100

Of which business quality 48 · Market factors (momentum, volatility) 32

Profitability 31
Margins and returns on capital today
Quality Growth 35
Are margins and returns improving?
Cashflow 33
Earnings quality: real cash, not paper profit
Fin. Strength 59
Balance sheet, leverage, solvency risk
Investment 63
Disciplined investing over empire-building
Low Volatility 72
Calm price path (market factor)
Momentum 19
Price trend over the last 3–12 months (market factor)
52W Momentum 8
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−7.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.4%
Start year 2020 (pandemic). Over 10 years: +12.5% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.5%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+1.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−0.6%
Dividend (yield on the price)2.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−0.6% vs 2.1%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 13%
Start year 2020 (pandemic)

Watch 1763, get fair value alerts →

Compare China Isotope Radiation Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 355 stocks

Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 49 · Below median
Fair Value upside +72.2% · Top 25%
Profitability
Return on equity (TTM) 8.2% · Above median
Return on assets 4.2% · Above median
Net margin (TTM) 4.5% · Below median
Operating margin (TTM) 15.7% · Top 25%
Growth and dividend
Revenue growth 4.4% · Below median
Dividend yield (TTM) 2.5% · Above median
Balance sheet
Debt / equity 0.33× · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (TTM) 11.0× · Cheapest 25%
P/B 0.69× · Cheapest 25%
P/S (TTM) 0.49× · Cheapest 25%
EV/EBITDA 2.1× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 9
FUTURE (revenue growth)22 · sector 31
PAST (return on equity)33 · sector 9
HEALTH (low debt)83 · sector 97
DIVIDEND (yield)50 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $101.29 $74.79 −26%
Medtronic plc MDT $87.09 $65.61 −25%
Stryker Corporation SYK $278.77 $306.65 +10%
Boston Scientific Corporation BSX $43.92 $48.31 +10%
Edwards Lifesciences Corporation EW $86.29 $81.94 −5%
Siemens Healthineers AG SHL €37.79 €35.19 −7%
DexCom, Inc DXCM $86.68 $95.35 +10%
GE HealthCare Technologies Inc GEHC $66.63 $70.37 +6%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.86 ¥169.25 +10%
Koninklijke Philips N.V PHIA €21.87 €15.23 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

China Isotope Radiation Corporation · Fair Value
HK$22.63 +42%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "China Isotope Radiation Corporation Fair Value". https://www.fairvalue-calculator.com/stock/1763

Frequently asked questions

Is China Isotope Radiation Corporation (1763) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of HK$22.63 versus a price of HK$13.14, about +72% upside (undervalued).
What is the fair value of 1763?
Our model-based fair value for China Isotope Radiation Corporation is HK$22.63 (as of Oct 1, 2026), built from audited fundamentals. The current price: HK$13.14.
What is the quality score of 1763?
China Isotope Radiation Corporation has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for China Isotope Radiation Corporation (1763)?
Our model-based price target is the fair value of HK$22.63 (as of Oct 1, 2026) from 17 valuation models. Cautious scenario HK$15.84, optimistic scenario HK$29.43. It is a calculation from audited fundamentals, not an analyst target.
What is the China Isotope Radiation Corporation stock forecast for 2026?
Our models put fair value at HK$22.63, about +72% upside versus a price of HK$13.14 (undervalued). Cautious scenario HK$15.84, optimistic scenario HK$29.43. The calculation is refreshed regularly with new filings.
What is the revenue of China Isotope Radiation Corporation (1763)?
China Isotope Radiation Corporation reported trailing-twelve-month revenue of about 7.3B CNY (latest available figure, as of Oct 1, 2026).
Does China Isotope Radiation Corporation pay a dividend?
China Isotope Radiation Corporation currently shows a dividend yield of about 2.48% relative to its recent price (as of Oct 1, 2026).
What is the intrinsic value of China Isotope Radiation Corporation (1763)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For China Isotope Radiation Corporation it is HK$22.63 per share (as of Oct 1, 2026), against a price of HK$13.14. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is China Isotope Radiation Corporation stock overvalued or undervalued in 2026?
As of Oct 1, 2026, 1763 trades below its calculated fair value: price HK$13.14, fair value HK$22.63, a gap of about +72% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1763?
No. The price is what the market pays today (HK$13.14); the fair value is what the company's own numbers justify (HK$22.63). For China Isotope Radiation Corporation the two are HK$9.49 per share apart. That gap is exactly why we show both numbers side by side.
How much is China Isotope Radiation Corporation worth?
The market values China Isotope Radiation Corporation at about HK$4.2B (market capitalisation, as of Oct 1, 2026). Per share that is HK$13.14; our models calculate a fair value of HK$22.63 per share.
What do the bullish and bearish scenarios say about 1763?
Our models span a range for China Isotope Radiation Corporation: cautious scenario HK$15.84, base HK$22.63, optimistic HK$29.43 per share (as of Oct 1, 2026, price HK$13.14). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1763?
China Isotope Radiation Corporation trades at a price-to-earnings ratio of 11.0 (as of Oct 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$22.63 is built from several models across several years. Other multiples: P/B 0.7, P/S 0.5, EV/EBITDA 2.1.
How solid is the balance sheet of China Isotope Radiation Corporation (1763)?
Balance-sheet figures for China Isotope Radiation Corporation (as of Oct 1, 2026): return on equity 8.2%, debt of 0.33 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is 1763 from its 52-week high?
China Isotope Radiation Corporation trades at HK$13.14, about 45% below its 52-week high of HK$24.06 and at the low of HK$13.14 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$22.63 is for.
Which stocks are comparable to China Isotope Radiation Corporation?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is China Isotope Radiation Corporation stock attractive at the current price?
The data as of Oct 1, 2026: price HK$13.14, calculated fair value HK$22.63 (+72%), Quality Score 49/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1763 calculated?
We run China Isotope Radiation Corporation through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$22.63, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. China Isotope Radiation Corporation currently trades 42 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of China Isotope Radiation Corporation (1763)?
The closing price on Sep 30, 2026 was HK$13.14. Our model-based fair value is HK$22.63, about +72% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with China Isotope Radiation Corporation right now?
The price is below even our cautious bear case (HK$15.84). The market is more pessimistic than our downside scenario. Solid quality (49/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (HK$15.84 to HK$29.43) leaves room in how you read the outcome.
Where does the earnings growth of China Isotope Radiation Corporation (1763) come from?
Earnings per share at China Isotope Radiation Corporation grew +4.2 % a year from 2015 to 2025. Broken into its drivers: revenue per share +14.4 %, EBIT margin −4.9 %, tax rate −2.3 %, residual (interest, one-offs) −1.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of China Isotope Radiation Corporation

How large is the market capitalisation of China Isotope Radiation Corporation (1763)?
The market capitalisation of China Isotope Radiation Corporation is HK$4.2B (≈ $536M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of China Isotope Radiation Corporation (1763)?
The price-to-sales ratio of China Isotope Radiation Corporation is 0.50 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of China Isotope Radiation Corporation (1763)?
The dividend yield of China Isotope Radiation Corporation is 2.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of China Isotope Radiation Corporation (1763)?
The net margin of China Isotope Radiation Corporation is 4.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of China Isotope Radiation Corporation (1763)?
The return on equity (ROE) of China Isotope Radiation Corporation is 8.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of China Isotope Radiation Corporation (1763)?
On an EBIT basis the return on assets of China Isotope Radiation Corporation is 7.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of China Isotope Radiation Corporation (1763)?
The operating margin of China Isotope Radiation Corporation is 15.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at China Isotope Radiation Corporation (1763)?
Revenue at China Isotope Radiation Corporation is growing +4.4% versus a year earlier (3y avg +4.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at China Isotope Radiation Corporation (1763)?
Earnings per share at China Isotope Radiation Corporation are growing −1.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does China Isotope Radiation Corporation (1763) generate?
The free cash flow of China Isotope Radiation Corporation is −48.4M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does China Isotope Radiation Corporation (1763) carry?
The net debt of China Isotope Radiation Corporation is 134M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch China Isotope Radiation Corporation in the live analysis

One click puts China Isotope Radiation Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.